All In Biotech

Drug Trial Radar · NCT04737486

A First-in-Human Study of AV-001 in Healthy Subjects

A Randomized, Double-blind, Placebo-controlled Phase 1 Single and Multiple-Dose Pharmacokinetic First-in-Human Study of AV-001 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Mar 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Dec 16, 2020

Primary completion

Mar 10, 2021

Study completion Mar 10, 2021

Sponsor

Lead sponsor
Vasomune Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase 1 randomized, double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) first-in-human study in healthy subjects. Safety and tolerability assessments will be conducted, and blood samples will be taken pre-dose and at several time points post-dose for pharmacokinetic (PK) and pharmacodynamics (PD) analysis.

Conditions

  • Covid19-associated ARDS
  • Covid19
  • ARDS

Interventions

  • AV-001Drug

    AV-001 (mpaBr) Cl for Injection 2.5 mg/mL

  • PlaceboOther

    D-PBS

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants experiencing drug-related adverse eventsTime frame: 8 days following a single intravenous dose (SAD) or 8 days following 7 consecutive daily intravenous doses (MAD)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medpace Clinical Pharmacology Unit

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.